Long term follow up of clinical trials of fludarabine (2-FaraAMP) showed that drug resistance due to mutations in the p53 pathway represents a significant challenge in the clinical management of CLL patients [1]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.